PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare ...

Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis ...

The latest announcement is out from Savara ( (SVRA) ).

-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested -- MOLBREEVI was granted Fast Track and Breakthrough Therapy ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced today that it has resubmitted the MOLBREEVI BLA to the FDA, with ...

Investing.com - Savara (NASDAQ:SVRA) stock advanced after Guggenheim reiterated its Buy rating and $11.00 price target following the company’s resubmission of its Biologics License Application (BLA) ...

LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA) announced Monday it has resubmitted its Biologics License Application (BLA) for MOLBREEVI to the U.S. Food and Drug Administration with FUJIFILM ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) said it has resubmitted its biologics license application for MOLBREEVI to the U.S. Food and Drug Administration, a key regulatory step toward approval ...

“Patients with pulmonary edema generally describe breathlessness. Sometimes they feel like they are suffocating or breathing ...

These selections offer a compelling snapshot of prevailing cultural and social trends, particularly among the young digital-native generation, over the past year. You may have overheard your children ...

SINGAPORE – A total of 143 people are being investigated by the police for their suspected involvement in scams where victims lost more than $3.82 million. This follows a two-week operation by ...